Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition)

of Male Reproductive System Oncology Society; Anti-Cancer Association China

doi:10.19401/j.cnki.1007-3639.2023.12.006

您当前的位置：

首页 >

文章列表页 >

Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition)

Guideline and Concensus | 更新时间：2025-12-31

- Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition)
- China Oncology Vol. 33, Issue 12, Pages: 1204-1214(2023)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.12.006
  CLC： R737.25
- Received：13 November 2023，
  
  Revised：2023-11-30，
  
  Published：30 December 2023
- 稿件说明：
移动端阅览
of Male Reproductive System Oncology Society, Anti-Cancer Association China. Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition)[J]. China Oncology, 2023, 33(12): 1204-1214.
DOI：

of Male Reproductive System Oncology Society, Anti-Cancer Association China. Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition)[J]. China Oncology, 2023, 33(12): 1204-1214. DOI： 10.19401/j.cnki.1007-3639.2023.12.006.

摘要

前列腺癌的发病率呈逐年上升趋势，正逐步成为影响中老年男性健康的重要疾病，高危前列腺癌是一种具有至少一种高危因素，存在较高转移风险和较差预后的前列腺癌类型，有研究指出10年内死于前列腺癌的患者中有66%来自高危前列腺癌。关于高危前列腺癌的治疗，围手术期进行新辅助治疗和辅助治疗的价值和意义存在争议。本共识采用循证医学方法，查阅和整理评估大量相关文献，进行质量等级评价、证据综合，编写初稿后，通过专家会议讨论、德尔菲问卷调查等方法，经过2轮逾33个不同城市、71家医院共计78名专家意见的调查汇总、归纳梳理和总结，依托中国抗癌协会男性生殖系统肿瘤专业委员会，形成《高危前列腺癌围手术期综合治疗专家共识（2023年版）》。针对高危前列腺癌围手术期的新辅助治疗和辅助治疗进行探索、讨论，希望为临床医师开展高危前列腺癌患者围手术期的治疗提供指导意见和规范依据。

Abstract

The incidence rate of prostate cancer is showing an upward trend year by year

gradually becoming an important disease affecting the health of middle-aged and elderly men. The high-risk prostate cancer is a type of prostate cancer with at least one high-risk factor

which has a higher risk of metastasis and a poorer prognosis. Studies have indicated that 66% of patients who die from prostate cancer within 10 years are having high-risk prostate cancer. There is controversy regarding the value and significance of neoadjuvant and adjuvant therapy during the perioperative period for high-risk prostate cancer treatment. The consensus adopted the evidence-based medical method

extensively reviewed and organized relevant literature

conducted quality grade evaluations and evidence synthesis. After drafting the initial version

expert meetings and Delphi questionnaire surveys were conducted. After two rounds of surveys collecting opinions from 78 experts across 33 different cities and 71 hospitals

the data were summarized and refined. Relying on Society of Male Reproductive System Oncology

China Anti-Cancer Association for the “expert consensus on perioperative comprehensive treatment for high-risk prostate cancer (2023 edition)” was formulated. The aim was to explore and discuss neoadjuvant and adjuvant treatments for high-risk prostate cancer during the perioperative period

hoping to provide clinical doctors with guidance and standardized criteria for treating perioperative patients with high-risk prostate cancer.

关键词

Keywords

references

GILLESSEN S , BOSSI A , DAVIS I D , et al . Management of patients with advanced prostate cancer. Part Ⅰ: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022 [J ] . Eur Urol , 2023 , 83 ( 3 ): 267 - 293 . DOI: 10.1016/j.eururo.2022.11.002 http://doi.org/10.1016/j.eururo.2022.11.002 https://linkinghub.elsevier.com/retrieve/pii/S0302283822027890 https://linkinghub.elsevier.com/retrieve/pii/S0302283822027890

RAVI P , KWAK L , XIE W L , et al . Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis [J ] . J Urol , 2022 , 208 ( 4 ): 838 - 845 . DOI: 10.1097/JU.0000000000002803 http://doi.org/10.1097/JU.0000000000002803

ASHRAFI A N , YIP W , ARON M . Neoadjuvant therapy in high-risk prostate cancer [J ] . Indian J Urol , 2020 , 36 ( 4 ): 251 - 261 . DOI: 10.4103/iju.IJU_115_20 http://doi.org/10.4103/iju.IJU_115_20 https://journals.lww.com/10.4103/iju.IJU_115_20 https://journals.lww.com/10.4103/iju.IJU_115_20

DEE E C , NEZOLOSKY M D , CHIPIDZA F E , et al . Prostate cancer-specific mortality burden by risk group among men with localized disease: implications for research and clinical trial priorities [J ] . Prostate , 2020 , 80 ( 13 ): 1128 - 1133 . DOI: 10.1002/pros.24041 http://doi.org/10.1002/pros.24041

ATKINS D , BEST D , BRISS P A , et al . Grading quality of evidence and strength of recommendations [J ] . BMJ , 2004 , 328 ( 7454 ): 1490 . DOI: 10.1136/bmj.328.7454.1490 http://doi.org/10.1136/bmj.328.7454.1490 https://www.bmj.com/lookup/doi/10.1136/bmj.328.7454.1490 https://www.bmj.com/lookup/doi/10.1136/bmj.328.7454.1490

D’AMICO A V , WHITTINGTON R , MALKOWICZ S B , et al . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J ] . JAMA , 1998 , 280 ( 11 ): 969 - 974 . DOI: 10.1001/jama.280.11.969 http://doi.org/10.1001/jama.280.11.969 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.280.11.969 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.280.11.969

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南-2022 [M ] . 北京 : 人民卫生出版社 , 2022 .

Chinese Society of Clinical Oncology Guidelines Working Committee . Chinese Society of Clinical Oncology (CSCO) prostate cancer diagnosis and treatment guidelines-2022 [M ] . Beijing : People's Medical Publishing House , 2022 .

MOHLER J . The 2010 NCCN clinical practice guidelines in oncology on prostate cancer [J ] . J Natl Compr Canc Netw , 2010 , 8 ( 2 ): 145 . DOI: 10.6004/jnccn.2010.0010 http://doi.org/10.6004/jnccn.2010.0010 https://jnccn.org/view/journals/jnccn/8/2/article-p145.xml https://jnccn.org/view/journals/jnccn/8/2/article-p145.xml

TRIULZI T , BIANCHINI G , DI COSIMO S , et al . The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial [J ] . Mol Oncol , 2022 , 16 ( 12 ): 2355 - 2366 . DOI: 10.3389/fonc.2022.868265 http://doi.org/10.3389/fonc.2022.868265 https://febs.onlinelibrary.wiley.com/toc/18780261/16/12 https://febs.onlinelibrary.wiley.com/toc/18780261/16/12

RUNDO L , BEER L , ESCUDERO SANCHEZ L , et al . Clinically interpretable radiomics-based prediction of histopathologic response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma [J ] . Front Oncol , 2022 , 12 : 868265 .

WANG X , ZHANG J , HAN B . Neoadjuvant hormonal therapy for prostate cancer: morphologic features and predictive parameters of therapy response [J ] . Adv Anat Pathol , 2022 , 29 ( 4 ): 252 - 258 . DOI: 10.1097/PAP.0000000000000347 http://doi.org/10.1097/PAP.0000000000000347

SHELLEY M D , KUMAR S , WILT T , et al . A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma [J ] . Cancer Treat Rev , 2009 , 35 ( 1 ): 9 - 17 . DOI: 10.1016/j.ctrv.2008.08.002 http://doi.org/10.1016/j.ctrv.2008.08.002

GRAVINA G L , FESTUCCIA C , GALATIOTO G P , et al . Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer [J ] . Urology , 2007 , 70 ( 4 ): 728 - 733 .

SCHULMAN C C , DEBRUYNE F M , FORSTER G , et al . 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T 2-3 N 0 M 0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer [J ] . Eur Urol , 2000 , 38 ( 6 ): 706 - 713 . DOI: 10.1159/000020366 http://doi.org/10.1159/000020366 https://www.karger.com/Article/FullText/20366 https://www.karger.com/Article/FullText/20366

TOSCO L , LAENEN A , BRIGANTI A , et al . The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer [J ] . Prostate Cancer Prostatic Dis , 2017 , 20 ( 4 ): 407 - 412 . DOI: 10.1038/pcan.2017.29 http://doi.org/10.1038/pcan.2017.29 https://www.nature.com/articles/pcan201729 https://www.nature.com/articles/pcan201729

DEVOS G , DEVLIES W , DE MEERLEER G , et al . Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer [J ] . Nat Rev Urol , 2021 , 18 ( 12 ): 739 - 762 . DOI: 10.1038/s41585-021-00514-9 http://doi.org/10.1038/s41585-021-00514-9

LOU D Y , FONG L . Neoadjuvant therapy for localized prostate cancer: examining mechanism of action and efficacy within the tumor [J ] . Urol Oncol , 2016 , 34 ( 4 ): 182 - 192 . DOI: 10.1016/j.urolonc.2013.12.001 http://doi.org/10.1016/j.urolonc.2013.12.001

NAYAK A L , FLAMAN A S , MALLICK R , et al . Do androgen-directed therapies improve outcomes in prostate cancer patients undergoing radical prostatectomy? A systematic review and meta-analysis [J ] . J De L'association Des Urol Du Can , 2021 , 15 ( 8 ): 269 - 279 .

TAPLIN M E , MONTGOMERY B , LOGOTHETIS C J , et al . Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase Ⅱ neoadjuvant study [J ] . J Clin Oncol , 2014 , 32 ( 33 ): 3705 - 3715 . DOI: 10.1200/JCO.2013.53.4578 http://doi.org/10.1200/JCO.2013.53.4578 https://ascopubs.org/doi/10.1200/JCO.2013.53.4578 https://ascopubs.org/doi/10.1200/JCO.2013.53.4578

EFSTATHIOU E , DAVIS J W , PISTERS L , et al . Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone [J ] . Eur Urol , 2019 , 76 ( 4 ): 418 - 424 . DOI: S0302-2838(19)30414-2 http://doi.org/S0302-2838(19)30414-2

MONTGOMERY B , TRETIAKOVA M S , JOSHUA A M , et al . Neoadjuvant enzalutamide prior to prostatectomy [J ] . Clin Cancer Res , 2017 , 23 ( 9 ): 2169 - 2176 . DOI: 10.1158/1078-0432.CCR-16-1357 http://doi.org/10.1158/1078-0432.CCR-16-1357

YANG X Y , ALLEN J C , ASLIM E J , et al . Patient-reported outcomes of a phase Ⅱ neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial [J ] . Int J Urol , 2022 , 29 ( 11 ): 1322 - 1330 . DOI: 10.1111/iju.v29.11 http://doi.org/10.1111/iju.v29.11 https://onlinelibrary.wiley.com/toc/14422042/29/11 https://onlinelibrary.wiley.com/toc/14422042/29/11

LEE L S , SIM A Y L , ONG C W , et al . NEAR trial: a single-arm phase Ⅱ trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer [J ] . Prostate Cancer Prostatic Dis , 2022 , 25 ( 4 ): 741 - 748 . DOI: 10.1038/s41391-022-00496-8 http://doi.org/10.1038/s41391-022-00496-8

US National Library of Medicine . ClinicalTrials.gov [EB/OL ] . [ 2023 - 10 - 10 ] . https://clinicaltrials.gov/ct2/show/NCT03767244.2021 https://clinicaltrials.gov/ct2/show/NCT03767244.2021 https://clinicaltrials.gov/ct2/show/NCT03767244.2021 .

GU W J , HAN W Q , LUO H , et al . Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2022 , 23 ( 10 ): 1249 - 1260 . DOI: 10.1016/S1470-2045(22)00507-1 http://doi.org/10.1016/S1470-2045(22)00507-1

GRAHAM L S , TRUE L D , GULATI R , et al . Targeting backdoor androgen synthesis through AKR1C3 inhibition: a presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer [J ] . Prostate , 2021 , 81 ( 7 ): 418 - 426 . DOI: 10.1002/pros.24118 http://doi.org/10.1002/pros.24118

MCKAY R R , XIE W L , YE H H , et al . Results of a randomized phase Ⅱ trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer [J ] . J Urol , 2021 , 206 ( 1 ): 80 - 87 . DOI: 10.1097/JU.0000000000001702 http://doi.org/10.1097/JU.0000000000001702 http://www.auajournals.org/doi/10.1097/JU.0000000000001702 http://www.auajournals.org/doi/10.1097/JU.0000000000001702

MCKAY R R , YE H H , XIE W L , et al . Evaluation of intense androgen deprivation before prostatectomy: a randomized phase Ⅱ trial of enzalutamide and leuprolide with or without abiraterone [J ] . J Clin Oncol , 2019 , 37 ( 11 ): 923 - 931 . DOI: 10.1200/JCO.18.01777 http://doi.org/10.1200/JCO.18.01777 https://ascopubs.org/doi/10.1200/JCO.18.01777 https://ascopubs.org/doi/10.1200/JCO.18.01777

EIGL B J , EGGENER S E , BAYBIK J , et al . Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer [J ] . Clin Cancer Res , 2005 , 11 ( 13 ): 4905 - 4911 .

KYRIAKOPOULOS C E , CHEN Y H , CARDUCCI M A , et al . Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase Ⅲ E3805 CHAARTED trial [J ] . J Clin Oncol , 2018 , 36 ( 11 ): 1080 - 1087 . DOI: 10.1200/JCO.2017.75.3657 http://doi.org/10.1200/JCO.2017.75.3657 https://ascopubs.org/doi/10.1200/JCO.2017.75.3657 https://ascopubs.org/doi/10.1200/JCO.2017.75.3657

PAN J H , CHI C F , QIAN H Y , et al . Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study [J ] . Urol Oncol , 2019 , 37 ( 12 ): 991 - 998 . DOI: S1078-1439(19)30285-6 http://doi.org/S1078-1439(19)30285-6

EASTHAM J A , HELLER G , HALABI S , et al . Cancer and leukemia group B90203 (alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer [J ] . J Clin Oncol , 2020 , 38 ( 26 ): 3042 - 3050 . DOI: 10.1200/JCO.20.00315 http://doi.org/10.1200/JCO.20.00315 https://ascopubs.org/doi/10.1200/JCO.20.00315 https://ascopubs.org/doi/10.1200/JCO.20.00315

氟唑帕利联合阿比特龙新辅助治疗局部高危前列腺癌的围手术期安全性期中分析. ASCO GU 2023: Poster 356. .[EB/OL ] . https://www.sohu.com/a/648782131_100148274 https://www.sohu.com/a/648782131_100148274 https://www.sohu.com/a/648782131_100148274 .

闫石 , 朱亚生 , 肖雨田 , 等 . 新型内分泌药物时代下的高危前列腺癌术前新辅助治疗研究进展 [J ] . 现代泌尿外科杂志 , 2022 : 1 - 6 .

YAN S , ZHU Y S , XIAO Y T , et al . Research progress on preoperative neoadjuvant therapy for high-risk prostate cancer in the era of new endocrine drugs [J ] . J Modern Urol , 2022 : 1 - 6 .

EFSTATHIOU E , ABRAHAMS N A , TIBBS R F , et al . Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification [J ] . Eur Urol , 2010 , 57 ( 6 ): 1030 - 1038 . DOI: 10.1016/j.eururo.2009.10.020 http://doi.org/10.1016/j.eururo.2009.10.020

TOSCO L , LAENEN A , GEVAERT T , et al . Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial [J ] . BMC Cancer , 2018 , 18 ( 1 ): 354 . DOI: 10.1186/s12885-018-4275-z http://doi.org/10.1186/s12885-018-4275-z

SEISEN T , VETTERLEIN M W , KARABON P , et al . Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis [J ] . Eur Urol , 2018 , 73 ( 3 ): 452 - 461 . DOI: S0302-2838(17)30697-8 http://doi.org/S0302-2838(17)30697-8

MESSING E M , MANOLA J , YAO J , et al . Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy [J ] . Lancet Oncol , 2006 , 7 ( 6 ): 472 - 479 . DOI: 10.1016/S1470-2045(06)70700-8 http://doi.org/10.1016/S1470-2045(06)70700-8

HUSSAIN M , TANGEN C M , THOMPSON I M Jr , et al . Phase Ⅲ intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921 [J ] . J Clin Oncol , 2018 , 36 ( 15 ): 1498 - 1504 .

SPAHN M , WEISS C , BADER P , et al . Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation [J ] . Urol Int , 2010 , 84 ( 2 ): 164 - 173 . DOI: 10.1159/000277593 http://doi.org/10.1159/000277593

WIEGEL T , BARTKOWIAK D , BOTTKE D , et al . Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial [J ] . Eur Urol , 2014 , 66 ( 2 ): 243 - 250 . DOI: 10.1016/j.eururo.2014.03.011 http://doi.org/10.1016/j.eururo.2014.03.011

HACKMAN G , TAARI K , TAMMELA T L , et al . Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension [J ] . Eur Urol , 2019 , 76 ( 5 ): 586 - 595 . DOI: S0302-2838(19)30525-1 http://doi.org/S0302-2838(19)30525-1

TILKI D , CHEN M H , WU J , et al . Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death [J ] . J Clin Oncol , 2021 , 39 ( 20 ): 2284 - 2293 . DOI: 10.1200/JCO.20.03714 http://doi.org/10.1200/JCO.20.03714 https://ascopubs.org/doi/10.1200/JCO.20.03714 https://ascopubs.org/doi/10.1200/JCO.20.03714

PARKER C C , CLARKE N W , COOK A D , et al . Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial [J ] . Lancet , 2020 , 396 ( 10260 ): 1413 - 1421 . DOI: 10.1016/S0140-6736(20)31553-1 http://doi.org/10.1016/S0140-6736(20)31553-1

KNEEBONE A , FRASER-BROWNE C , DUCHESNE G M , et al . Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial [J ] . Lancet Oncol , 2020 , 21 ( 10 ): 1331 - 1340 . DOI: S1470-2045(20)30456-3 http://doi.org/S1470-2045(20)30456-3

SARGOS P , CHABAUD S , LATORZEFF I , et al . Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 10 ): 1341 - 1352 . DOI: S1470-2045(20)30454-X http://doi.org/S1470-2045(20)30454-X

GUPTA M , PATEL H D , SCHWEN Z R , et al . Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit [J ] . BJU Int , 2019 , 123 ( 2 ): 252 - 260 . DOI: 10.1111/bju.14241 http://doi.org/10.1111/bju.14241

MARRA G , VALERIO M , HEIDEGGER I , et al . Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review [J ] . Eur Urol Oncol , 2020 , 3 ( 5 ): 565 - 581 . DOI: 10.1016/j.euo.2020.08.005 http://doi.org/10.1016/j.euo.2020.08.005

SACHDEV S , CARROLL P , SANDLER H , et al . Assessment of postprostatectomy radiotherapy as adjuvant or salvage therapy in patients with prostate cancer: a systematic review [J ] . JAMA Oncol , 2020 , 6 ( 11 ): 1793 - 1800 . DOI: 10.1001/jamaoncol.2020.2832 http://doi.org/10.1001/jamaoncol.2020.2832 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769895 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769895

VALE C L , FISHER D , KNEEBONE A , et al . Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data [J ] . Lancet , 2020 , 396 ( 10260 ): 1422 - 1431 . DOI: 10.1016/S0140-6736(20)31952-8 http://doi.org/10.1016/S0140-6736(20)31952-8

AHLGREN G M , FLODGREN P , TAMMELA T L J , et al . Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 Scandinavian prostate cancer group 12 trial [J ] . Eur Urol , 2018 , 73 ( 6 ): 870 - 876 . DOI: 10.1016/j.eururo.2018.01.012 http://doi.org/10.1016/j.eururo.2018.01.012 https://linkinghub.elsevier.com/retrieve/pii/S0302283818300216 https://linkinghub.elsevier.com/retrieve/pii/S0302283818300216

SHIOTA M , BLAS L , ETO M . Current status and future perspective on the management of lymph node-positive prostate cancer after radical prostatectomy [J ] . Cancers (Basel) , 2022 , 14 ( 11 ): 2696 . DOI: 10.3390/cancers14112696 http://doi.org/10.3390/cancers14112696 https://www.mdpi.com/2072-6694/14/11/2696 https://www.mdpi.com/2072-6694/14/11/2696

Views

7040

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress and future prospects in local and systemic treatment of early breast cancer

Current status and prospect of perioperative treatment of stage Ⅲ melanoma

Expert consensus on metformin adjuvant therapy in malignant tumor patients with diabetes mellitus type 2 (2022 edition)

The current data and challenge of radiotherapy in the case management of gastric cancer

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Related Author

Junjie LI

Yu XU

Yong CHEN

Jilong YANG

Guannan ZHU

of Onco-endocrinology of Chinese Anti-Cancer Association Society

Gang CAI

Shubei WANG

Related Institution

Department of Breast Surgery, Fudan University Shanghai Cancer Center/Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University

Department of Dermatology, Xijing Hospital, Air Force Military Medical University (Fourth Military Medical University)

Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Molecular Cancer Epidemiology

Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer

Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰